信使核糖核酸(messenger ribonucleic acid, mRNA)是一种极具潜力的治疗药物, 在免疫学、肿瘤学、疫苗和先天性代谢疾病等研究领域具有广阔前景。但由于其自身不稳定且易被核酸酶降解所以需要高效的递送载体。脂质纳米颗粒(lipid nanoparticle, LNP)具有易于配制、稳定性高 ...

然而，其不稳定性及易被核酸酶降解的特性，使得高效递送系统成为了mRNA成功成药的关键。脂质纳米颗粒(LNP)被公认为是最成熟的mRNA递送载体，因其具备很强的细胞摄取能力和良好的生物相容性，但其在肝脏的积累却成为了技术推广的主要障碍。为了解决这一 ...

【导读】用于信使核糖核酸（mRNA）递送的脂质纳米颗粒（LNPs）已取得显著进展，但脂质纳米颗粒介导的脱氧核糖核酸（DNA）递送在临床上仍面临诸多挑战。1月13日，美国贝勒医学院研究人员在期刊《Molecular Cancer》上发表了研究论文，题为 ...

LNP that are used today for mRNA therapies are up to 200,000-250,000 times more active than those that were originally developed for small interfering RNA therapies. In addition, the LNP has also ...

NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Ningbo No.2 Hospital, Ningbo, Zhejiang 315010, P. R. China Guoke Ningbo Life Science and Health Industry Research Institute, Ningbo, Zhejiang 315000, P. R. China ...

PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.